New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota
Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor...
Main Authors: | Marina Lorente-Picón, Ariadna Laguna |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/3/433 |
Similar Items
-
The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder
by: Piranavie Srikantha, et al.
Published: (2019-04-01) -
Polyphenols-gut microbiota interplay and brain neuromodulation
by: Stefania Filosa, et al.
Published: (2018-01-01) -
The use of microbiota-modulating agents for the treatment of neurological disorders by influencing the microbiota-gut-brain axis
by: T. Breugelmans, et al.
Published: (2020-06-01) -
Effects of the Human Gut Microbiota on Cognitive Performance, Brain Structure and Function: A Narrative Review
by: Katie Louise Tooley
Published: (2020-09-01) -
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
by: Jing Liu, et al.
Published: (2020-10-01)